



January 29, 2018

Adamas Announces Closing of Its Public Offering of Common Stock, and Full Exercise of Underwriters' Option to Purchase Additional Shares

EMERYVILLE, Calif., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the closing of its previously announced underwritten public offering of its common stock. Adamas sold 3,000,000 shares of its common stock, and the underwriters have exercised their option in full to purchase an additional 450,000 shares pursuant to the full exercise of the underwriters' option, at a price to the public of \$41.50 per share. The aggregate gross proceeds from this offering are expected to be \$143,175,000, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Adamas. The purchase of the 3,000,000 shares closed on January 26, 2018. The sale of the 450,000 shares is expected to close on January 30, 2018, subject to customary closing conditions. All of the shares of common stock were offered by Adamas.

BofA Merrill Lynch, Leerink Partners and Evercore ISI acted as book-running managers for the offering. A shelf registration statement relating to the shares was filed with the Securities and Exchange Commission on November 3, 2016, and became effective on November 21, 2016. The offering was made only by means of a prospectus supplement. Copies of the prospectus supplement and accompanying prospectus relating to the public offering may be obtained by contacting BofA Merrill Lynch, NC1-004-03, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attn: Prospectus Department, email: dg.prospectus_requests@baml.com; Leerink Partners, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525 ext. 6132 or by email at.Syndicate@Leerink.com; or Evercore ISI, Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, or by telephone at (888) 474-0200 or by email at ecm.prospectus@evercore.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Adamas Pharmaceuticals, Inc.

Adamas is a pharmaceutical company committed to developing and commercializing products and product candidates for the treatment of chronic neurological disorders.

For questions, please contact:

Ashleigh Barreto
Director, Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc.
510-450-3567

 [Primary Logo](#)

Source: Adamas Pharmaceuticals, Inc.

News Provided by Acquire Media